Results 151 to 160 of about 456,565 (226)

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real-World Data Sources for Fit-for-Purpose Studies. [PDF]

Clin Pharmacol Ther
Zebachi S, Tanniou J, Bakker E, de Vries ST, Di Bidino R, Xoxi E, Glaser A, Savarese G, Hillert J, Mol PGM, Plueschke K, Amzal B, Hayek GY, Moreira J.   +13 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Are Current Patient-Reported Outcome Measures Fit for Purpose to Evaluate Unicompartmental Knee Arthroplasty? [PDF]

J Clin Med
Bayram JM, Clement ND, Hall AJ, Walmsley P, Clarke JV.   +4 more
europepmc   +1 more source

Census Data: Fit for Purpose? [PDF]

Environment and Planning A: Economy and Space, 2007
openaire   +2 more sources

Universities fit for purpose

, 2023
Megan Lindow, Anthony Egeru, Kay Muir Leresche   +2 more
openaire   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Recommendations on fit-for-purpose criteria to establish quality management for microphysiological systems and for monitoring their reproducibility. [PDF]

Stem Cell Reports
Pamies D, Ekert J, Zurich MG, Frey O, Werner S, Piergiovanni M, Freedman BS, Keong Teo AK, Erfurth H, Reyes DR, Loskill P, Candarlioglu P, Suter-Dick L, Wang S, Hartung T, Coecke S, Stacey GN, Wagegg BA, Dehne EM, Pistollato F, Leist M.   +20 more
europepmc   +2 more sources

Evaluating health and social care integration in England's Pioneer programme: The challenges of undertaking research in service delivery and research regulatory systems that are not fit for purpose. [PDF]

J Health Serv Res Policy
Durand MA, Erens B, Wistow G, Hoomans T, Manacorda T, Mays N.   +5 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment. [PDF]

Front Med (Lausanne)
Eertink JJ, Bahce I, Waterton JC, Huisman MC, Boellaard R, Wunder A, Thiele A, Menke-van der Houven van Oordt CW.   +7 more
europepmc   +1 more source